Videos

Pharmacists have been central to vaccine distribution since the COVID-19 pandemic, and as viruses spread, they must continue urging patients to stay updated on vaccinations to prevent severe illness and reduce hospitalizations.

Obinutuzumab is effective in reducing proteinuria and preserving kidney function in lupus nephritis, with consistent benefits across high-disease activity subgroups.

LAIs offer a variety of benefits, from improved medication adherence and relapse prevention to enhanced quality of life for individuals with schizophrenia.

Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.

Pharmacists are integral to setting patient expectations, monitoring liver health, and ensuring adherence to long-term follow-up for optimal outcomes with etranacogene dezaparvovec.

Panelists discuss how comprehensive educational resources are essential for empowering patients with TD to better understand their condition, actively participate in their treatment decisions, and achieve optimal outcomes through improved self-management and adherence.

Panelists discuss how pharmacists employ multiple strategies to support medication adherence in older adults with TD, including simplifying dosing regimens, utilizing medication synchronization programs, providing medication packaging solutions, conducting regular follow-up calls, and collaborating closely with prescribers and care teams to develop and adjust personalized treatment plans that address individual patient needs and barriers to care.

If approved, gepotidacin (GSK) will be a new oral agent added to the treatment paradigm for urinary tract infections (UTIs).

Panelists discuss how health care professionals recommend physician consultations for persistent symptoms, complex medical histories, diagnostic uncertainties, specialist needs, urgent conditions, preventive care, medication management, and comprehensive health assessments.

Panelists explain how health care professionals evaluate menopause symptoms using validated questionnaires, symptom tracking, clinical interviews, hormonal tests, and patient-reported outcome measures to comprehensively assess severity and quality-of-life impact.

Pharmacists must consider drug Interactions, allergies, and comorbidities when treating patients with urinary tract infections (UTIs).

Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.

Panelists discuss how antibody-drug conjugates (ADCs) show varying efficacy and adverse event (AE) profiles based on their payload potency, linker stability, and drug-to-antibody ratio. Cleavable linkers enable targeted drug release but may increase toxicity, while noncleavable designs offer better stability. Payload selection impacts both therapeutic index and AEs, with more potent warheads requiring careful optimization of targeting and release kinetics.

Research has demonstrated a reduction in hospitalization risk associated with the use of LAIs, but some barriers can prevent the wider adoption of this approach.

The ongoing "quad-demic" of influenza, norovirus, RSV, and COVID is creating heightened health risks, making prevention through hygiene, masking, and vaccination critical.

Intravenous immunoglobulin therapy for patients with CIDP requires navigating insurance coverage and prolonged therapy.

Phil Vigeant shares benefits and considerations of plant-based protein powders, highlighting the pharmacist's role in recommending quality plant-based protein powders.

According to Pranav Garimella, pharmacists are essential in counseling patients with CKD on the appropriate use of semaglutide.

Gaps in education about biosimilars, particularly among pharmacists, patients, and prescribers, are a significant barrier to wider adoption.

Etranacogene dezaparvovec offers a long-term, cost-effective solution for hemophilia B by providing sustained factor IX expression but requires careful patient selection and post-infusion liver monitoring.

Panelists discuss how pharmacists must carefully consider factors like age-related changes in drug metabolism, comorbid conditions, concurrent medications, fall risk, and individual patient response when dosing and titrating VMAT2 inhibitors in older adults, typically recommending a "start low, go slow" approach while closely monitoring for both efficacy and adverse effects.

Panelists discuss how pharmacists serve as essential medication experts by providing comprehensive counseling on VMAT2 inhibitors, including proper administration, expectations for symptom improvement, potential side effects, and drug interactions, while playing a vital role in monitoring older adult patients through regular check-ins, medication therapy management services, and collaboration with the healthcare team to optimize treatment outcomes.

Melody Smith, MD, MS, discusses how microbiome modulation may influence CAR T-cell therapy toxicity and outcomes, highlighting potential future interventions and clinical integration challenges.

Melody Smith, MD, MS, discusses how the intestinal microbiome influences CAR T-cell therapy outcomes, highlighting the negative impact of certain antibiotics and the potential role of dietary interventions in improving treatment efficacy.

Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.

Panelists discuss how menopause represents a complex physiological transition characterized by hormonal fluctuations, reproductive system changes, and multifaceted symptoms affecting physical, psychological, and metabolic health. Comprehensive patient education, personalized management strategies, and holistic support are crucial for navigating this transformative life stage.

Panelists discuss how antibody-drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic payloads, enabling precise targeting of breast cancer (BC) cells through specific antigen recognition. Upon binding, the ADC-antigen complex is internalized, releasing the toxic payload inside cancer cells while largely sparing healthy tissue. This targeted approach offers improved efficacy and reduces systemic toxicity compared with traditional chemotherapy's broad cytotoxic effects.

Panelists discuss how the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for HER2-negative breast cancer (BC) have evolved to recognize HER2-low (IHC 1+  or 2+/ISH-negative) and HER2-ultra low (IHC 0) as distinct categories. These classifications, particularly HER2-low, guide eligibility for targeted therapies such as trastuzumab deruxtecan, expanding treatment options beyond traditional chemotherapy for previously categorized HER2-negative patients.

Panelists discuss how pharmacists play a crucial role in optimizing health outcomes for women with complex health needs through comprehensive medication management, personalized consultations, and interdisciplinary collaboration. They provide targeted medication therapy, monitor drug interactions, offer medication counseling, manage chronic conditions, support reproductive health, and help patients navigate complex treatment regimens with expertise and compassionate care.

Identifying and managing IVIG-related side effects early on in treatment can improve efficacy and safety for patients with CIDP.